RBC Capital Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on Edwards Lifesciences (NYSE:EW) but lowers the price target from $101 to $85.
July 25, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital analyst Shagun Singh maintains an Outperform rating on Edwards Lifesciences but lowers the price target from $101 to $85.
The Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates a more cautious outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100